Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

H. Quach*, D. Joshua, J. Ho, J. Szer, A. Spencer, S. Harrison, P. Mollee, A. Roberts, N. Horvath, D. Talaulikar, B. To, A. Zannettino, R. Brown, L. Catley, B. Augustson, W. Jaksic, J. Gibson, H. M. Prince

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)

    Abstract

    Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

    Original languageEnglish
    Pages (from-to)335-343
    Number of pages9
    JournalInternal Medicine Journal
    Volume45
    Issue number3
    DOIs
    Publication statusPublished - 1 Mar 2015

    Fingerprint

    Dive into the research topics of 'Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group'. Together they form a unique fingerprint.

    Cite this